Literature DB >> 23907144

Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.

Alon Kahana1, Francis P Worden, Victor M Elner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23907144      PMCID： PMC4104203          DOI： 10.1001/jamaophthalmol.2013.4430

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  5 in total

1.  Oral hedgehog-pathway inhibitors for basal-cell carcinoma.

Authors:  John T Lear
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

2.  Risk factors for orbital exenteration in periocular Basal cell carcinoma.

Authors:  Adriana Iuliano; Diego Strianese; Giovanni Uccello; Agostino Diplomatico; Sabrina Tebaldi; Giulio Bonavolontà
Journal:  Am J Ophthalmol       Date:  2011-10-06       Impact factor: 5.258

3.  Orbital invasion by periocular basal cell carcinoma.

Authors:  Igal Leibovitch; Alan McNab; Timothy Sullivan; Garry Davis; Dinesh Selva
Journal:  Ophthalmology       Date:  2005-04       Impact factor: 12.079

4.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Authors:  Aleksandar Sekulic; Michael R Migden; Anthony E Oro; Luc Dirix; Karl D Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Jennifer A Low; Howard M Mackey; Robert L Yauch; Richard A Graham; Josina C Reddy; Axel Hauschild
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

5.  Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

Authors:  Jean Y Tang; Julian M Mackay-Wiggan; Michelle Aszterbaum; Robert L Yauch; Joselyn Lindgren; Kris Chang; Carol Coppola; Anita M Chanana; Jackleen Marji; David R Bickers; Ervin H Epstein
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245
  5 in total
  11 in total

Review 1.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.

Authors:  Meydan Ben Ishai; Alon Tiosano; Eyal Fenig; Guy Ben Simon; Iftach Yassur
Journal:  JAMA Ophthalmol       Date:  2020-07-01       Impact factor: 7.389

3.  [Young male patient with unusual space-occupying lesion of the lower eyelid].

Authors:  Alexander C Rokohl; Heike Löser; Joel M Mor; Niklas Loreck; Konrad R Koch; Ludwig M Heindl
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

Review 4.  Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas.

Authors:  Vivian T Yin; Helen Merritt; Bita Esmaeli
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

5.  Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.

Authors:  Hakan Demirci; Francis Worden; Christine C Nelson; Victor M Elner; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Nov-Dec       Impact factor: 1.746

6.  Myths in the Diagnosis and Management of Orbital Tumors.

Authors:  Kaan Gündüz; Özge Yanık
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Oct-Dec

7.  Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.

Authors:  Kai Yuen Wong; Kate Fife; John T Lear; Richard D Price; Amer J Durrani
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-07-21

Review 8.  Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.

Authors:  Yingyun Shi; Renbing Jia; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2017-05-08       Impact factor: 4.147

9.  Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.

Authors:  Maxwell G Su; Luke B Potts; Jonathan H Tsai
Journal:  Am J Ophthalmol Case Rep       Date:  2020-05-23

10.  Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.

Authors:  Alon Kahana; Shelby P Unsworth; Christopher A Andrews; May P Chan; Scott C Bresler; Christopher K Bichakjian; Alison B Durham; Hakan Demirci; Victor M Elner; Christine C Nelson; Denise S Kim; Shannon S Joseph; Paul L Swiecicki; Francis P Worden
Journal:  Oncologist       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.